Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProMIS Neurosciences Inc.PMN · Entity 6643 | Director · Chief Operating Officer | October 26, 2023 | October 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProMIS Neurosciences Inc.
Report date October 26, 2023 · Filed October 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2033-10-26 | Direct | 12,500 |
Reported balance
After 2023-10-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-10-26 · Grant · Acquired 12,500 · Balance 12,500 F1: 25% of the shares subject to this option shall vest on October 26, 2024, and the balance shall vest ratably over 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest on October 26, 2024, and the balance shall vest ratably over 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2023 Filed Oct 30, 2023 19:51 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0000950170-23-056504 · ownership.xml · derivative · entry 1 Malenfant Gavin T. · CIK 0001927060 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-10-26 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on October 26, 2024, and the balance shall vest ratably over 36 months. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 16:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantWarrants to purchase Common Shares · Derivative | 2,660 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0000899243-23-018463 · doc4.xml · derivative · entry 2 Malenfant Gavin T. · CIK 0001927060 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,660 Underlying: Common Shares · 2,660 shares Expires 2029-02-21 F1 · kind: On August 23, 2023, pursuant to a Unit Purchase Agreement entered into by the Company with selected investors (the "Offering"), the Reporting Person acquired 2,660 common share units (each, a "Common Share Unit"), each unit consisting of one of the Company's common shares, no par value (the "Common Shares"), and one warrant to purchase one Common Share. The purchase price for each Common Share Unit was $1.88 per Common Share Unit. F1 · price: On August 23, 2023, pursuant to a Unit Purchase Agreement entered into by the Company with selected investors (the "Offering"), the Reporting Person acquired 2,660 common share units (each, a "Common Share Unit"), each unit consisting of one of the Company's common shares, no par value (the "Common Shares"), and one warrant to purchase one Common Share. The purchase price for each Common Share Unit was $1.88 per Common Share Unit. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 16:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantCommon Shares | 2,660 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-018463 · doc4.xml · nonDerivative · entry 1 Malenfant Gavin T. · CIK 0001927060 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,660 F1 · kind: On August 23, 2023, pursuant to a Unit Purchase Agreement entered into by the Company with selected investors (the "Offering"), the Reporting Person acquired 2,660 common share units (each, a "Common Share Unit"), each unit consisting of one of the Company's common shares, no par value (the "Common Shares"), and one warrant to purchase one Common Share. The purchase price for each Common Share Unit was $1.88 per Common Share Unit. F1 · price: On August 23, 2023, pursuant to a Unit Purchase Agreement entered into by the Company with selected investors (the "Offering"), the Reporting Person acquired 2,660 common share units (each, a "Common Share Unit"), each unit consisting of one of the Company's common shares, no par value (the "Common Shares"), and one warrant to purchase one Common Share. The purchase price for each Common Share Unit was $1.88 per Common Share Unit. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.